On January 23, 2017, Atlas Genetics Ltd. closed the trandaction. The company announced that it has received £28.4 million in series D round of funding. The company received additional £14.05 million in its second tranche.

The tranche included participation from existing investor Consort Medical plc (LSE:CSRT) for £3.1 million, alongside existing shareholders, RMI Partners, Novartis Venture Fund, a fund managed by Novartis Venture Funds, Johnson & Johnson Innovation - JJDC, Inc., BB Biotech Ventures G.P., and South West Ventures Fund, a fund managed by Technology Venture Partners, LLP. Pursuant to the transaction, the stake of Consort Medical plc (LSE:CSRT) shall increase to 15.2%.